2-hydroxyethyl octadecanoate : An octadecanoate ester obtained by formal condensation between the carboxy group of octadecanoic (stearic) acid and one of the hydroxy groups of ethylene glycol. It is an ingredient in many personal care products and cosmetics. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 24762 |
| CHEMBL ID | 2355383 |
| CHEBI ID | 167626 |
| CHEBI ID | 32027 |
| SCHEMBL ID | 10412 |
| MeSH ID | M0053906 |
| Synonym |
|---|
| ethylene glycol monostearate se |
| unii-6yly96tql6 |
| 6yly96tql6 , |
| glycol stearate se |
| 86418-55-5 |
| glycol monostearate se |
| tegin g |
| octadecanoic acid 2-hydroxyethyl ester |
| CHEBI:167626 |
| AKOS015843173 |
| myrj 52s |
| peg 42 |
| emcol h 35-a |
| peg 100ms |
| cerasynt 660 |
| ethofat 60/20 |
| nonex 29 |
| empilan cq-100 |
| nsc-31811 |
| cremophor a |
| myrj |
| mys 40 |
| perphinol 45/100 |
| nissan nonion s 15 |
| arosurf 1855e40 |
| nonex 28 |
| prodhybase 4000 |
| peg-150 stearate |
| nonion s 4 |
| myrj 51 |
| nonion s 15 |
| myrj 53 |
| cerasynt m |
| crill 20,22,23 |
| stabilisant .delta.-118 |
| s 541 |
| peg 1000ms |
| nikkol mys 40 |
| nikkol mys 4 |
| 9004-99-3 |
| lipal 400-s |
| prodhybase p |
| stearoks 920 |
| nonex 54 |
| peg 600ms |
| stearoxa-6 |
| empilan cp-100 |
| clearate g |
| myrj 52 |
| lipal 15s |
| lactine |
| usaf ke-9 |
| ethofat 60/25 |
| peg-8 stearate |
| nsc31811 |
| nonex 63 |
| cerasynt mn |
| akyporox s 100 |
| s 1004 |
| soromin-sg |
| peg stearate |
| nissan nonion s-2 |
| nonion s 2 |
| glycols, monostearate |
| ionet ms-1000 |
| usaf ke-12 |
| cithrol 10ms |
| nikkol mys-25 |
| mys 45 |
| stenol 8 |
| pegosperse s 9 |
| s 1012 |
| s 1054 |
| kessco x-211 |
| x-489-r |
| lx 3 |
| cithrol ps |
| nikkol mys |
| nonex 36 |
| emunon 3115 |
| lipo-peg 4-s |
| myrj 45 |
| myrj 59 |
| s 1116 |
| emanon 3113 |
| myrj 49 |
| nikkol mys 45 |
| nonex 53 |
| emery 15393 |
| trydet sa 40 |
| stearox 6 |
| stearox 920 |
| usaf ke-14 |
| stearoks 6 |
| emerest 2640 |
| lamacit ca |
| ethofat 60/15 |
| peg-40 stearate |
| 111-60-4 |
| magi 45 |
| pms no. 1 |
| pms no. 2 |
| emanon 3199 |
| trydet sa series |
| stabilisant delta-118 |
| 17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl octadecanoate |
| slovasol mks 16 |
| emulphor vt-650 |
| peg-10 stearate |
| stearic acid, 2-hydroxyethyl ester |
| octadecanoic acid, 2-hydroxyethyl ester |
| crill 20,21,22, 23 |
| 2-hydroxyethyl octadecanoate |
| 2-hydroxyethyl stearate |
| D01542 |
| myrj 52 (tn) |
| macrogol ester (inn) |
| monthybase |
| ethylene glycol stearate |
| ethylene glycol, monostearate |
| lipo egms |
| parastarin |
| brn 1794033 |
| empilan 2848 |
| glycol monostearate |
| clindrol seg |
| prodhybas n |
| usaf ke-11 |
| s 151 |
| monthyle |
| glycol stearate |
| emerest 2350 |
| prodhybase ethyl |
| einecs 203-886-9 |
| stearic acid, monoester with ethylene glycol |
| ethylene glycol monostearate |
| tego-stearate |
| ivorit |
| sedetol |
| L001305 |
| NCGC00188435-01 |
| tox21_113036 |
| cas-111-60-4 |
| dtxcid006881 |
| dtxsid5026881 , |
| unii-0324g66d0e |
| 0324g66d0e , |
| FT-0626337 |
| glycol stearate [vandf] |
| glycol stearate [ii] |
| glycol stearate [inci] |
| ethylene glycol monostearate [who-dd] |
| SCHEMBL10412 |
| ethyleneglycol monostearate |
| peg40 stearate |
| CHEMBL2355383 |
| schercemol egms |
| alkamuls egms/c |
| pegosperse 50 ms |
| ablunol egms |
| alkamuls seg |
| cerasynt mn (salt/mix) |
| cerasynt m (salt/mix) |
| W-109413 |
| macrogol ester |
| CHEBI:32027 , |
| Q5572621 |
| mfcd00051465 |
| n,n-bis-(1-phenyl-ethyl)-malonamide |
| BS-48654 |
| CS-0440899 |
| peg 2000 ms |
| poly(oxy-1,2-ethanediyl), a-(1-oxooctadecyl)-w-hydroxy- |
| F71256 |
| F71203 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Role | Description |
|---|---|
| nonionic surfactant | A surfactant with an uncharged hydrophilic headgroup. |
| emulsifier | The chemical role played by a substance that stabilizes an emulsion by increasing its kinetic stability. |
| plasticiser | Any compound that is used as an additive to increase the plasticity or fluidity of a substance, particularly but not exclusively to synthetic polymers. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| octadecanoate ester | A fatty acid ester obtained by condensation of the carboxy group of stearic acid with the hydroxy group of any alcohol or phenol. |
| long-chain primary fatty alcohol | A long-chain fatty alcohol in which the hydroxy group is attached to a methylene (CH2) group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 2.6609 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 9.4392 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 35.4813 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| virion membrane | Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.48) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||